Journal of Clinical & Translational Endocrinology (Mar 2022)

Use of estrogen supplementation is associated with higher quality of life scores in women with cystic fibrosis

  • Malinda Wu,
  • Neha Arora,
  • Viranuj Sueblinvong,
  • William R. Hunt,
  • Vin Tangpricha

Journal volume & issue
Vol. 27
p. 100292

Abstract

Read online

The association of estrogen supplementation use and quality of life in women with cystic fibrosis (CF) is not well characterized. In this cross-sectional study, women with CF completed quality of life questionnaires during a routine CF clinic visit. The use of estrogen supplementation was associated with higher quality of life scores in all domains of the CF questionnaire-revised (CFQ-R) and was significant in the role limitations and respiratory domains. Most participants who were not currently using estrogen supplementation had previously used estrogen supplementation. Most participants had used estrogen to regulate menses, prevent pregnancy and control symptoms around menses. Use of estrogen supplementation was not associated with differences in life-space mobility or screening for sexual dysfunction. This is the largest study to date investigating the association of estrogen supplementation and quality of life in women with CF. Prospective randomized studies are needed to clarify the association of estrogen supplementation and quality of life in women with CF.

Keywords